SP1 and gastric cancer: Gastric cancer patients whose tumors highly expressed ZEB2 or Sp1 had a lower overall survival than those whose tumors did not (n = 631, P = 0.00053 and P = 0.000024 for ZEB2 and Sp1, respectively) when survival within previously published data sets was analyzed using kmPlotter (Figure 7C).